Should B-Type Natriuretic Peptide Be Measured Routinely to Guide the Diagnosis and Management of Chronic Heart Failure?

Circulation

Volumn 108, Issue 24, 2003, Pages 2950-2953

  Packer, Milton ^a  

^a College of Physicians and Surgeons ^*  (United States)

Author keywords

Diagnosis; Editorials; Heart failure; Natriuretic peptides; Tests

Indexed keywords

ALDOSTERONE ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BRAIN NATRIURETIC PEPTIDE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT;

DIAGNOSTIC TEST; HEART FAILURE; HUMAN; MEASUREMENT; MEDICAL DECISION MAKING; MEDICAL EXAMINATION; PRACTICE GUIDELINE; PRIORITY JOURNAL; REVIEW;

CARDIAC OUTPUT, LOW; CHRONIC DISEASE; HUMANS; NATRIURETIC PEPTIDE, BRAIN; TREATMENT OUTCOME;

EID: 0346365091     PISSN: 00097322     EISSN: None     Source Type: Journal    
DOI: 10.1161/01.CIR.0000109205.35813.8E     Document Type: Review

References (12)

1. Maisel AS, Krishnaswamy P, Nowak RM, et al. Rapid measurement of B-type natriuretic peptide in the emergency diagnosis of heart failure. N Engl J Med. 2002;347:161-167.
2. Wang TJ, Larson MG, Levy D, et al. Impact of age and sex on plasma natriuretic peptide levels in healthy adults. Am J Cardiol. 2002;90:254-258.
3. Ishii J, Nomura M, Ito M, et al. Plasma concentration of brain natriuretic peptide as a biochemical marker for the evaluation of right ventricular overload and mortality in chronic respiratory disease. Clin Chim Acta. 2000;301:19-30.
4. Hetmanski DJ, Sparrow NJ, Curtis S, et al. Failure of plasma brain natriuretic peptide to identify left ventricular systolic dysfunction in the community. Heart. 2000;84:440-441.
5. Maisel A. B-type natriuretic peptide levels: diagnostic and prognostic in congestive heart failure: what's next? Circulation. 2002;105:2328-2331.
6. Tang WHW, Girod JP, Lee MJ, et al. Plasma B-type peptide levels in ambulatory patients with established chronic symptomatic systolic heart failure. Circulation. 2003;108:2964-2966.
7. McNairy M, Gardetto N, Clopton P, et al. Stability of B-type natriuretic peptide levels during exercise in patients with congestive heart failure: implications for outpatient monitoring with B-type natriuretic peptide. Am Heart J. 2002;143:406-411.
8. Lee SC, Stevens TL, Sandberg SM, et al. The potential of brain natriuretic peptide as a biomarker for New York Heart Association class during the outpatient treatment of heart failure. J Card Fail. 2002;8:149-154.
9. Berger R, Huelsman M, Stecker K, et al. B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation. 2002;105:2391-2396.
10. Aaronson KD, Schwartz JS, Chen TM, et al. Development and prospective validation of a clinical index to predict survival in ambulatory patients referred for cardiac transplant evaluation. Circulation. 1997;95:2660-2667.
11. Troughton RW, Frampton CM, Yandle TG, et al. Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet. 2000;355:1126-1130.
12. Packer M, Poole-Wilson PA, Armstrong PW, et al. Comparative effects of low and high doses of the angiotensin-converting enzyme inhibitor, lisinopril, on morbidity and mortality in chronic heart failure. Circulation. 1999;100:2312-2318.